ENDO INTERNATIONAL PLC (NASDAQ:ENDP) Files An 8-K Costs Associated with Exit or Disposal ActivitiesItem 2.05. Costs Associated with Exit or Disposal Activities.
On July 21, 2017, the Registrant announced that after completing a comprehensive review of its manufacturing network, the Registrant will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the “2017 U.S. Generic Pharmaceuticals restructuring initiative”). The closure of the facilities is expected to take place over the next 12 to 18 months. The Registrant’s Board of Directors approved the 2017 U.S. Generic Pharmaceuticals restructuring initiative on July 18, 2017. The Huntsville locations have been impacted by declining volumes of commoditized products and these restructuring actions are intended to better match manufacturing capacity to projected future demand.
As a result of the 2017 U.S. Generic Pharmaceuticals restructuring initiative, the Registrant's workforce is expected to be reduced by approximately 875 positions, including approximately 35 open positions, and the Registrant expects to incur total pre-tax restructuring-related expenses of approximately $325 million, including total estimated cash outlays of approximately $60 million, substantially all of which will be paid by the end of 2018. The estimated restructuring charges consist of accelerated depreciation charges of approximately $165 million, asset impairment charges related to identifiable intangible assets and certain property, plant and equipment of approximately $90 million, charges to increase excess inventory reserves of approximately $10 million, employee separation, retention and other benefit-related costs of approximately $40 million and certain other charges of approximately $20 million. The Registrant expects to realize approximately $55 million to $65 million in annual net run rate pre-tax cost savings by the fourth quarter of 2018.
Any charges associated with the 2017 U.S. Generic Pharmaceuticals restructuring initiative will be included in the U.S. Generic Pharmaceuticals segment. Associated impairment charges, charges to increase excess inventory reserves and certain other charges will be recorded during the second quarter of 2017 and reported in the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, expected to be filed no later than August 9, 2017. Employee separation, retention and certain other employee benefit-related costs will be expensed ratably over the requisite service period. Other costs that will be incurred including, but not limited to, contract termination fees and product technology transfer costs, will be expensed as incurred.
The estimated expenses, charges, costs and savings noted above are subject to a number of assumptions. Actual results may differ materially as a result of various important factors, including the risks and uncertainties described under the heading “Cautionary Note Regarding Forward-Looking Statements” in the copy of the press release included as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated by reference herein.
Item 2.05. Material Impairments.
The information required by this Item 2.05 is included under Item 2.05 of this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.05.Financial Statements and Exhibits.
(d)Exhibits.
Endo International plc ExhibitEX-99.1 2 july2017restructuringpr.htm EXHIBIT 99.1 – PRESS RELEASE July2017RestructuringPR Exhibit 99.1 Endo to Restructure Manufacturing NetworkDUBLIN,…To view the full exhibit click here
